Roche reports positive results for experimental obesity drug

Swiss pharma giant Roche said on Tuesday that a phase II clinical trial of its experimental obesity drug CT-388 had given positive results. +Get the most important news from Switzerland in your inbox In the study participants who received the active ingredient CT-388 once a week for 48 weeks lost over 20% of their body weight on average, Roche said in a press release on Monday. The higher the dose administered, the greater the weight loss. The effects were particularly clear at the highest dose tested. Almost all participants lost at least 5% of their body weight, around half even lost more than 20% and a quarter lost over 30%. Drug well tolerated According to Roche, the metabolism also benefited. Blood glucose levels normalised in almost three-quarters of the study participants with a preliminary stage of diabetes, significantly more than in the comparison group without the active ingredient. The drug was well tolerated overall. The most common side effects related to the ... Full story here Are you the author? Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: Featured,newsletter